H.R. 6674 – Better Care for PFAS Patients Act of 2023

AI-Generated Summary

Updated January 20, 2026 at 1:32 PM UTC

The Better Care for PFAS Patients Act of 2023 requires the Agency for Toxic Substances and Disease Registry (ATSDR) to work with the National Academies (or another qualified entity) to assess the health effects of per‑ and polyfluoroalkyl substances (PFAS) that can be measured in human tissue and to develop clinical recommendations. The law mandates that up‑to‑date clinical guidance be created and shared with state and local health officials and health‑care providers, helping patients affected by PFAS exposure.

Key Provisions

ATSDR must enter into an agreement with the National Academies (or another appropriate entity) within 60 days of enactment to assess PFAS health effects and create clinical recommendations.
The initial assessment and recommendations must be completed within two years, with updates required at least every five years or more often if needed.
ATSDR must issue, post online, and distribute up‑to‑date clinical guidance on PFAS health effects no later than five years after the agreement, and repeat this every five years or as science dictates.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

2 earlier actions

HouseCommittee Latest Action

Referred to the Subcommittee on Environment, Manufacturing, and Critical Materials.

Environment Subcommittee

December 8, 2023

View full timeline

HouseIntro Referral

Introduced in House

December 7, 2023

HouseIntro Referral

Referred to the House Committee on Energy and Commerce.

Energy and Commerce Committee

December 7, 2023

HouseCommittee

Referred to the Subcommittee on Environment, Manufacturing, and Critical Materials.

Environment Subcommittee

December 8, 2023

Bill Text

Latest available legislative text

Reading Mode

Raw Text PDF XML

Introduced in HouseIssued December 7, 2023

I

118th CONGRESS

1st Session

H. R. 6674

IN THE HOUSE OF REPRESENTATIVES

December 7, 2023

Mr. Kildee (for himself and Mr. Lawler) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To provide for the periodic issuance of up-to-date clinical guidance on addressing the health effects of per- and polyfluoroalkyl substances (PFAS), and for other purposes.

1.

Short title

This Act may be cited as the Better Care for PFAS Patients Act of 2023.

2.

PFAS health effects assessment, recommendations, and guidance

(a)

Periodic assessment and recommendations

(1)

Agreement

The Director of the Agency for Toxic Substances and Disease Registry (in this section referred to as the Director) shall enter into an agreement with the National Academies of Sciences, Engineering, and Medicine (or another appropriate entity if the National Academies declines to enter into such agreement) under which the National Academies or the other appropriate entity agrees—

(A)

to assess the health effects of per- and polyfluoroalkyl substances (in this section referred to as PFAS) that can be measured in human tissues;

(B)

to formulate clinical recommendations on addressing such health effects;

(C)

not later than 2 years after the date of entry into such agreement, to complete the initial assessment under subparagraph (A) and formulate the initial recommendations under subparagraph (B); and

(D)

to update the most recent assessment and recommendations under this paragraph—

(i)

every 5 years; or

(ii)

more frequently as determined necessary by the Director based on an assessment of the science.

(2)

Timing of entry into agreement

The Director shall enter into the agreement required by paragraph (1) not later than 60 days after the date of enactment of this Act.

(b)

Up-to-Date guidance

Based on the results of the most recent assessment and recommendations under subsection (a), the Director, in consultation with the entity with which the Director enters into the agreement under subsection (a), shall—

(1)

not later than 5 years after the date of entry into the agreement required by subsection (a)—

(A)

issue up-to-date clinical guidance on addressing the health effects of PFAS;

(B)

post such guidance on the public website of the Agency for Toxic Substances and Disease Registry; and

(C)

disseminate such guidance to State and local public health authorities and appropriate health care professionals; and

(2)

every 5 years thereafter, or more frequently as determined necessary by the Director based on an assessment of the science, issue, post, and disseminate up-to-date guidance as described in paragraph (1).